About precision biosciences inc. - DTIL
Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's proprietary genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane on January 26, 2006 and is headquartered in Durham, NC.
DTIL At a Glance
Precision BioSciences, Inc.
302 East Pettigrew Street
Durham, North Carolina 27701
| Phone | 1-919-314-5512 | Revenue | 34.26M | |
| Industry | Biotechnology | Net Income | -46,609,000.00 | |
| Sector | Health Technology | Employees | 68 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
DTIL Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.557 |
| Price to Book Ratio | 1.086 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.677 |
| Enterprise Value to Sales | -0.975 |
| Total Debt to Enterprise Value | -0.862 |
DTIL Efficiency
| Revenue/Employee | 503,882.353 |
| Income Per Employee | -685,426.471 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.236 |
DTIL Liquidity
| Current Ratio | 13.322 |
| Quick Ratio | 13.322 |
| Cash Ratio | 12.968 |
DTIL Profitability
| Gross Margin | 91.965 |
| Operating Margin | -152.195 |
| Pretax Margin | -136.029 |
| Net Margin | -136.029 |
| Return on Assets | -32.055 |
| Return on Equity | -62.714 |
| Return on Total Capital | -38.502 |
| Return on Invested Capital | -45.546 |
DTIL Capital Structure
| Total Debt to Total Equity | 31.229 |
| Total Debt to Total Capital | 23.797 |
| Total Debt to Total Assets | 18.656 |
| Long-Term Debt to Equity | 29.595 |
| Long-Term Debt to Total Capital | 22.552 |